Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
Journal of Clinical Medicine · 12.04.2023 · 12 (8) · 2824
DOI: 10.3390/jcm12082824 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.04.2023. Verfasst von Anjay Rastogi und 1 weiteren Autor:innen. Beteiligte Einrichtung: David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to improve cardiovascular and renal outcomes in patients with established cardiovascular disease, chronic kidney disease (CKD), and heart failure (HF) with reduced or preserved ejection fraction. Clinical benefit has been substantiated in patients with and without type 2 diabetes (T2D). Consequently, SGLT2is have an increasingly important role in HF and CKD management that extends beyond T2D treatment. Their pleiotropic pharmacological effects underlying their cardiovascular and renal benefits are not completely understood but include significant effects beyond blood glucose reduction. SGLT2is inhibit the reabsorption of glucose and sodium in the proximal tubule which, in addition to lowering blood glucose, activates tubuloglomerular feedback, leading to reduced glomerular hydrostatic pressure and the mitigation of glomerular filtration rate loss. SGLT2is have diuretic and natriuretic effects, leading to decreased blood pressure, preload, and left ventricular (LV) filling pressure, and improvements in other surrogates of afterload. In HF, SGLT2is mitigate the risks of hyperkalemia and ventricular arrhythmia and improve LV dysfunction. SGLT2is also reduce sympathetic tone and uric acid levels, increase hemoglobin levels, and are postulated to have anti-inflammatory properties. This narrative review discusses the multifactorial and interrelated pharmacological mechanisms underlying the cardiovascular and renal benefits of SGLT2is.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
- Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
- Baim Institute for Clinical Research, Boston, MA 02215, USA.
ORCID-Profile: James L Januzzi
Förderung
- AstraZeneca
Zitieren
APA
Rastogi, A., & Januzzi, J. L. (2023). Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. Journal of Clinical Medicine, 12(8), 2824. https://doi.org/10.3390/jcm12082824
Vancouver
Rastogi A, Januzzi JL. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. Journal of Clinical Medicine. 2023;12(8):2824. doi:10.3390/jcm12082824
BibTeX
@article{Rastogi2023,
author = {Rastogi, Anjay and Januzzi, James L},
title = {Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {8},
pages = {2824},
doi = {10.3390/jcm12082824}
}
EUVIMED